Zevra Therapeutics: Asymmetric Risk-Reward Setup In Ultra-Rare Disease Market

Core Insights - Zevra Therapeutics (ZVRA) reported Q3 FY25 earnings on November 5th, 2025, with net revenues of $26.1 million, of which $22.4 million was generated from their primary revenue driver, MIPLYFFA, indicating a revenue increase of 605% compared to the same quarter last year [1] Company Performance - The company achieved a significant revenue growth of 605% year-over-year, highlighting its strong performance in the market [1] - MIPLYFFA remains the primary revenue driver, contributing a substantial portion of the total revenues [1]